Akèy › Kansè poumon › Michigan › Lansing
Etid klinik pou Kansè poumon nan Lansing, MI
11 etid pou Kansè poumon ap chèche patisipan nan sit nan ak bò kote Lansing (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Ap rekriteFaz 3
- University of Michigan Health - Sparrow Lansing, Lansing
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- University of Michigan Health - Sparrow Lansing, Lansing
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
Ap rekriteFaz 3
- University of Michigan Health - Sparrow Lansing, Lansing
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Ap rekriteFaz 3
- University of Michigan Health - Sparrow Lansing, Lansing
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Ap rekriteFaz 3
- University of Michigan Health - Sparrow Lansing, Lansing
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
Ap rekriteFaz 3
- Karmanos Cancer Institute at McLaren Greater Lansing, Lansing
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
Ap rekriteFaz 3
- Karmanos Cancer Institute at McLaren Greater Lansing, Lansing
- University of Michigan Health - Sparrow Lansing, Lansing
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Ap rekriteFaz 2
- University of Michigan Health - Sparrow Lansing, Lansing
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Ap rekriteFaz 2
- University of Michigan Health - Sparrow Lansing, Lansing
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Ap rekriteFaz 2/3
- University of Michigan Health - Sparrow Lansing, Lansing
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, Lansing
Etid Kansè poumon nan lòt vil
- Houston, TX78 etid
- Boston, MA62 etid
- New York City, NY60 etid
- Los Angeles, CA45 etid
- Washington, DC41 etid
- Arlington, VA41 etid
- Chicago, IL41 etid
- Nashville, TN40 etid
- Baltimore, MD40 etid
- St. Louis, MO39 etid
- Columbus, OH37 etid
- Philadelphia, PA36 etid
Lòt etid nan Lansing
- Kansè pwostat10 etid
- Kansè nan tete10 etid
- Kansè Poumon ki pa ti selil9 etid
- Kansè (tout kalite)6 etid
- Kansè larinks5 etid
- Kansè vejik5 etid
- Twoub Somnolans Eksestif5 etid
- Kansè kolorektal4 etid
- Kansè renn (Kasinom selil renn)4 etid
- Kansè kolon4 etid
- Kasinom Selil Transizyonèl (Urotelyal)4 etid
- Karsinòm selil skuamèz tèt ak kou4 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.